The venom of the Gila monster has been instrumental in developing treatments for diabetes and obesity via GLP-1 receptor agonists like Ozempic and Wegovy. Specific components of the venom, particularly the peptide exendin-4, stimulate insulin release and regulate appetite by mimicking the naturally occurring GLP-1 hormone. This discovery stemmed from pioneering work by endocrinologist Daniel J. Drucker and Dr. John Eng, who explored how Gila monsters’ unique metabolic processes could be harnessed to create long-lasting therapeutic agents for managing blood sugar levels and reducing body weight.
The venom of the Gila monster, through its peptide exendin-4, has paved the way for new diabetes and obesity treatments such as Ozempic and Wegovy.
Daniel J. Drucker’s pioneering research in the late 1990s identified the potential of GLP-1 receptor agonists, transforming diabetes treatment by utilizing the properties of Gila monster venom.
Collection
[
|
...
]